The global cancer immunotherapy market is projected to experience significant growth, with varying projections ranging from around $100 billion to $273 billion by 2028. The market is driven by factors such as increasing adoption of targeted therapy, high prevalence of cancer, and ongoing research & new approvals for treatment methods. Companies like Amgen Inc., Astrazeneca, Bayer AG, Bristol-Myers Squibb, ELI Lilly and Company, Janssen Global Services LLC, Johnson and Johnson, Merck, Novartis, Pfizer, and F. Hoffmann-La Roche Ltd. are actively involved in this market, with a focus on monoclonal antibodies and cancer immunotherapy indications.

Cancer Immunotherapy Market Projections